Sage Journals: Discover world-class research

Abstract

OBJECTIVE: To compare product attributes, preferences, and expected compliance associated with triamcinolone acetonide aqueous (TAA-AQ), fluticasone propionate (FP), and mometasone furoate (MF) nasal sprays in patients with allergic rhinitis.

STUDY DESIGN AND SETTING: Data from 2 randomized, double-blind crossover studies with identical design were pooled (N = 215). Patients completed a 14-item sensory attributes questionnaire immediately after each product, and stated their preference and expected compliance with a prescription after receiving all products.

RESULTS: Compared with FP and MF, TAA-AQ was associated with significantly less odor and greater liking of odor (P < 0.001); and less taste, less dryness of nose/throat, less aftertaste, and greater overall liking (P < 0.05). Significantly more patients preferred most a prescription of TAA-AQ (50.0%) versus FP (25.0%; P < 0.001) and MF (25.0%; P < 0.001), and would “definitely comply” with TAA-AQ (62.5%) versus FP (49.0%; P < 0.01) and MF (51.0%; P < 0.01).

CONCLUSION: TAA-AQ was associated with significantly more positive sensory attributes, higher preference, and better expected compliance than FP and MF.

SIGNIFICANCE: Patients' preferences for the sensory attributes of an intranasal corticosteroid may affect adherence to treatment.

Get full access to this article

View all access options for this article.

References

Storms

Meltzer

Nathan

. The economic impact of allergic rhinitis. J Allergy Clin Immunol 1997;99:S820–4

D'Alonzo

. GE Scope and impact of allergic rhinitis. J Am Osteopath Assoc 2002;102 (6 Suppl 2):S2–6

Conner

. Evaluation and treatment of the patient with allergic rhinitis. J Fam Pract 2002;51:883–4, 887–90

Nash

Sullivan

Mackowiak

. Optimizing quality of care and cost effectiveness in treating allergic rhinitis in a managed care setting. Am J Manag Care 2000;6 (1 Suppl):S3–15

Centers for Disease Control and Prevention. National Center for Health Statistics. Allergies/Hay Fever. Vital and Health Statistics Series 10, No. 205. Available at: http://www.cdc.gov/nchs/fastats/allergies.htm. Accessed February 24, 2003

Stempel

Woolf

. The cost of treating allergic rhinitis. Curr Allergy Asthma Rep 2002;2:223–30

Rosenwasser

. Treatment of allergic rhinitis. Am J Med 2002;113 (Suppl 9A):17S–24S

Willsie

. Improved strategies and new treatment options for allergic rhinitis. J Am Osteopath Assoc 2002;102 (6 Suppl2):S7–14

Storms

. Rethinking our approach to allergic rhinitis management. Ann Allergy Asthma Immunol 2002;88 (4 Suppl 1):30–5

10.

LaForce

. Use of nasal steroids in managing allergic rhinitis. J Allergy Clin Immunol 1999;103 (3 Pt 2):S388–94

11.

Nielson

Mygind

Dahl

. Intranasal corticosteroids for allergic rhinitis: Superior relief? Drugs 2001;61:1563–79

12.

Yanez

Rodrigo

. Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: A systematic review with meta-analysis. Ann Allergy Asthma Immunol 2002;89:479–84

13.

Corren

. Intranasal corticosteroids for allergic rhinitis: How do different agents compare? J Allergy Clin Immunol 1999;104 (4 Pt 1):S144–9

14.

Gross

Jacobs

Woodworth

. Comparative efficacy, safety, and effect on quality of life of triamcinolone acetonide and fluticasone propionate aqueous nasal sprays in patients with fall seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2002;89:56–62

15.

Small

Houle

Day

. A comparison of triamcinolone acetonide nasal aerosol spray and fluticasone propionate aqueous solution spray in the treatment of spring allergic rhinitis. J Allergy Clin Immunol 1997;100:592–5

16.

Trangsrud

Whitaker

Small

. Intranasal corticosteroids for allergic rhinitis. Pharmacotherapy 2002;22:1458–67

17.

Mandl

Nolop

Lutsky

. Comparison of once daily mometasone furoate and fluticasone propionate aqueous nasal sprays for the treatment of perennial rhinitis. Ann Allergy Asthma Immunol 1997;79:370–8

18.

Blaiss

. Efficacy, safety, and patient preference of inhaled nasal corticosteroids: A review of pertinent published data. Allergy Asthma Proc 2001;22 (6 Suppl 1):S5–10

19.

Dupclay

L Doyle

. Assessment of intranasal corticosteroid use in allergic rhinitis: Benefits, costs, and patient preferences. Am J Manag Care 2002;8:S335–40

20.

Kaliner

. Patient preferences and satisfaction with prescribed nasal steroids for allergic rhinitis. Allergy Asthma Proc 2001;22 (6 Suppl 1):S11–5

21.

Bachert

El-Akkad

. Patient preferences and sensory comparisons of three intranasal corticosteroids for the treatment of allergic rhinitis. Ann Allergy Asthma Immunol 2002;89:292–7

22.

Schoenwetter

Dupclay

Garcia

. A comparison of patients' preferences for the sensory attributes of triamcinolone acetonide aqueous, mometasone furoate, and fluticasone propionate. Poster presented at Western Society of Allergy, Asthma, and Immunology annual meeting, January, 2003, Maui, HI

23.

Shah

Miller

Pethick

. Two multicenter, randomized, single-blind, single-dose crossover studies of specific sensory attributes of budesonide aqueous nasal spray and fluticasone propionate nasal spray. Clin Ther 2003;25:2198–214

Evaluation of Patients' Preferences for Triamcinolone Acetonide Aqueous,Fluticasone Propionate,and Mometasone Furoate Nasal Sprays in Patients with Allergic Rhinitis

Abstract

Get full access to this article

References